Oppenheimer Downgrades Aurinia Pharmaceuticals to Perform

Oppenheimer analyst Justin Kim downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Perform.

Oppenheimer analyst Justin Kim downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) from Outperform to Perform.

Total
0
Shares
Related Posts
Read More

Impinj Hits A High Note As Analyst Optimistic On RFID Expansion, Bumps Up Price Target

Needham analyst James Ricchiuti raises Impinj's price target to $115, maintaining a Buy rating. The optimistic outlook is driven by PI's impressive Q4 2023 projections, surpassing revenue and adjusted EBITDA estimates. Management's confidence in capitalizing on opportunities with key enterprise customers and expansion in retail use cases positions PI for strong growth in FY24 and FY25.

PI